AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

- 1.-11. (Canceled)
- 12. (Currently Amended) An amino acid having the formula:

$$R^{12}-A$$
 $()_s$ $C(O)R^{14}$ R^{11} N R^{11}

wherein

A is a member selected from O, NH, and S;

 R^{11} , $R^{11'}$, and R^{12} are independently selected from H, substituted or unsubstituted alkyl and water-soluble polymers, with the proviso that at least two of R^{11} , $R^{11'}$, and R^{12} are water-soluble polymer moieties; and

R¹⁴ is a member selected from OH, reactive functional groups, a group comprising a saccharide moiety or a group that is linked to a earrier is a nucleotide sugar or comprises a saccharide moiety conjugated to a member selected from a peptide and a lipid; and

s is an integer selected from between 1 and 5.

- 13. (Original) The amino acid according to claim 12, wherein said water-soluble polymer moieties comprise poly(ethylene glycol).
- 14. (Previously Presented) The amino acid according to claim 12, having the formula:

$$R^{12}-S$$
 $C(O)R^{14}$ R^{11} R^{11} .

15. (Previously Presented) The amino acid according to claim 14, having the formula:

$$H_3C-(OCH_2CH_2)_nOCH_2CH_2-S$$
 $C(O)R^{14}$
 R^{11}
 $C(O)O-(CH_2CH_2O)_m-CH_3$

wherein

m is an integer selected from between 1 and 10,000; and n is an integer selected from between 1 and 10.

- 16. (Canceled)
- 17. (Currently Amended) The amino acid according to claim $\frac{16}{12}$, wherein $\frac{R^{14}}{12}$ said-saecharide moiety is a nucleotide sugar.
- 18. (Currently Amended) The amino acid according to claim $\frac{16}{12}$, wherein $\frac{R^{14}}{12}$ comprises a said saccharide moiety is conjugated to a member selected from a peptide and a lipid.
- 19. (Currently Amended) The amino acid according to claim 46 12, wherein said saccharide moiety is conjugated to a member selected from an amino acid and a glycosyl residue of a peptide.
- 20. (Previously Presented) The amino acid according to claim 19, wherein said saccharide moiety is a glycosyl linking group between an amino acid and a peptide.
- 21. (Previously Presented) The amino acid according to claim 20, wherein said saccharide moiety is an intact glycosyl linking group between an amino acid and a peptide.
- 22. (Currently Amended) A pharmaceutical formulation comprising the amino acid according to claim 12 wherein R¹⁴ comprises a carrier molecule that is a member selected from therapeutic moieties, and a pharmaceutically acceptable carrier.

23.-38. (Canceled)

- 39. (Currently Amended) The amino acid according to Claim 13, wherein said poly(ethylene glycol) moieties have a molecular weight selected from 5 Kd, 10 Kd, 20 Kd, and 30 Kd.
- 40. (Currently Amended) The amino acid according to Claim 13, wherein said poly(ethylene glycol) moieties have a molecular weight of 20 Kd.
 - 41. (New) The amino acid according to claim 12, having the formula:

wherein n is an integer selected from 1 to 20,000.

42. (New) The amino acid according to claim 12, having the formula:

wherein

R¹⁵ is H, a nucleotide phosphate, or a bond to an amino acid of a peptide or to a glycosyl moiety that is directly bound to an amino acid of a peptide, or indirectly bound to an amino acid of a peptide by its conjugation to a glycosyl residue attached to the amino acid;

L is a linker; and

n is an integer selected from 1 to 20,000.

- 43. (New) The amino acid according to claim 42, wherein L comprises an -NH-moiety.
- 44. (New) A pharmaceutical formulation comprising the amino acid according to claim 17 and a pharmaceutically acceptable carrier.
- 45. (New) A pharmaceutical formulation comprising the amino acid according to claim 18 and a pharmaceutically acceptable carrier.
- 46. (New) A pharmaceutical formulation comprising the amino acid according to claim 41 and a pharmaceutically acceptable carrier.
- 47. (New) A pharmaceutical formulation comprising the amino acid according to claim 42 and a pharmaceutically acceptable carrier.
- 48. (New) A pharmaceutical formulation comprising the amino acid according to claim 43 and a pharmaceutically acceptable carrier.